Advertisement
U.S. markets open in 6 hours 30 minutes

Repligen Corporation (RGEN)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
194.25+4.32 (+2.27%)
At close: 04:00PM EDT
194.25 0.00 (0.00%)
After hours: 04:41PM EDT

Repligen Corporation

Building 1
Suite 100 41 Seyon Street
Waltham, MA 02453
United States
781 250 0111
https://www.repligen.com

Sector(s)Healthcare
IndustryMedical Instruments & Supplies
Full Time Employees1,783

Key Executives

NameTitlePayExercisedYear Born
Mr. Anthony J. HuntCEO & Director1.59M9.43M1964
Mr. James R. BylundChief Operating Officer820.26k292.13k1964
Ms. Christine GebskiSenior Vice President of Filtration & Chromatography625.76kN/A1969
Mr. Ralf KuriyelSenior Vice President of Research & Development661.75k814.23k1959
Mr. Olivier LoeillotPresident & Chief Commercial OfficerN/AN/AN/A
Mr. Jason K. GarlandChief Financial OfficerN/AN/A1974
Mr. Keith Lee RobinsonChief Information OfficerN/AN/AN/A
Ms. Sondra S. NewmanGlobal Head of Investor RelationsN/AN/AN/A
Ms. Kimberly A. CornwellGeneral CounselN/AN/AN/A
Dr. Jaime M. Humara Ph.D.Senior Vice President of MarketingN/AN/AN/A
Amounts are as of December 31, 2022 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products. The company's chromatography products include OPUS pre-packed chromatography columns, which are used in the purification of biologics; and OPUS smaller-scale columns that are used in the high throughput process development screening, viral clearance validation studies, and scale down validation of chromatography processes. It also offers ELISA test kits; and chromatography resins under the CaptivA brand. In addition, the company provides filtration products, such as XCell Alternating Tangential Flow systems that are filtration devices used in upstream perfusion and cell culture processing; TangenX flat sheet cassettes, which are used in downstream biologic drug concentration, buffer exchange, and formulation processes; KrosFlo tangential flow filtration and tangential flow depth filtration systems; Spectra/Por laboratory and process dialysis products, and ProConnex TFDF flow paths. Further, it provides process analytics products, such as slope spectroscopy systems under the SoloVPE, FlowVPE, and FlowVPX brands. The company sells its products to life sciences, biopharmaceutical, and diagnostics companies; laboratory researchers; and contract manufacturing organizations. Repligen Corporation has collaboration agreements with Navigo Proteins GmbH to develop multiple affinity ligands. The company was incorporated in 1981 and is headquartered in Waltham, Massachusetts.

Corporate Governance

Repligen Corporation’s ISS Governance QualityScore as of March 1, 2024 is 2. The pillar scores are Audit: 5; Board: 3; Shareholder Rights: 1; Compensation: 4.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.